FCM
ABUS icon

FourWorld Capital Management’s Arbutus Biopharma ABUS Stock Holding History

FourWorld Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,020,910
Closed -$4.63M – 23
2025
Q3 		$4.63M Sell
1,020,910
-205,800
-17% -$756K 7.32% 4
2025
Q2 		$3.79M Hold
1,226,710
– – 2.55% 7
2025
Q1 		$4.28M Hold
1,226,710
– – 2.75% 6
2024
Q4 		$4.01M Sell
1,226,710
-1,745,817
-59% -$6.42M 2.08% 6
2024
Q3 		$11.4M Hold
2,972,527
– – 6.59% 4
2024
Q2 		$9.19M Sell
2,972,527
-28,000
-0.9% -$84K 5.5% 5
2024
Q1 		$7.74M Buy
3,000,527
+1,909,676
+175% +$4.95M 4.94% 6
2023
Q4 		$2.73M Sell
1,090,851
-251,056
-19% -$492K 1.47% 10
2023
Q3 		$2.72M Hold
1,341,907
– – 0.51% 18
2023
Q2 		$3.09M Sell
1,341,907
-658,183
-33% -$1.71M 0.51% 15
2023
Q1 		$6.06M Hold
2,000,090
– – 1.39% 12
2022
Q4 		$4.66M Hold
2,000,090
– – 6.41% 5
2022
Q3 		$3.82M Buy
2,000,090
+199,090
+11% +$469K 6.05% 6
2022
Q2 		$4.88M Buy
1,801,000
+253,261
+16% +$648K 7.77% 4
2022
Q1 		$4.61M Buy
+1,547,739
New +$4.74M 2.86% 5

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

FourWorld Capital Management's ABUS Position: Q4 2025 in Review

FourWorld Capital Management sold out of Arbutus Biopharma (ABUS) in Q4 2025, closing a stake of 1,020,910 shares — an estimated $4.63M sold.

FourWorld Capital Management first reported a position in ABUS in Q1 2022 and held it in 15 quarters. The position peaked at $11.4M in Q3 2024. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

  • FourWorld Capital Management reported no remaining Arbutus Biopharma position as of Q4 2025 after selling out during the quarter.
  • FourWorld Capital Management sold 1,020,910 Arbutus Biopharma shares in Q4 2025, an estimated $4.63M.
  • FourWorld Capital Management first reported a position in Arbutus Biopharma in Q1 2022 and held it in 15 quarters.
  • FourWorld Capital Management's Arbutus Biopharma position peaked at $11.4M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on FourWorld Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.